Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

NCT02638909 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of Enrollment

Conditions

Colorectal Adenocarcinoma
Cholangiocarcinoma
Pancreatic Adenocarcinoma
Hepatocellular Adenocarcinoma
Gastric Adenocarcinoma
Esophageal Adenocarcinoma

Interventions

DRUG: ceritinib

Sponsor

Criterium, Inc.

Collaborators

[object Object]
[object Object]